Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (9103)	9/11/2003 11:42:32 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Seems to me the final data is in No, I don't think that's correct. There's more data to come as more patients reach the 12 month follow-up mark (or die). As Bulba said, if the patients who have not yet reached 12 months mark follow the same pattern as those that have, they would demonstrate a strong statistically significant effect. It's just a few months - but then thse patients have little in the way of treatment options and you may well see a stronger effect if the drug is used earlier. Peter